Halozyme Therapeutics revenue and financials
$109.72Change from previous close: +1.30%Absolute change: +$1.41
In the fiscal year ended December 2025, Halozyme Therapeutics reported revenue of $1.4B (+37.55% year over year). Net income was $316.89M, a net margin of 22.7%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +37.55%
- 2025 vs 2024
- Net income growth
- −28.64%
- 2025 vs 2024
- Net margin
- 22.7%
- 2024: 43.7%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 241 | 180 | 219 | 179 | 99.7 | 154 | 178 | 115 | 55.8 | 129 | 102 | 132 |
| Depreciation and amortization | 34.0 | 33.7 | 26.7 | 20.4 | 20.5 | 20.4 | 20.4 | 20.4 | 20.3 | 20.2 | 20.7 | 20.6 |
| Capital expenditure | -4.2 | -3.7 | -1.4 | -3.0 | -1.6 | -1.0 | -3.1 | -1.5 | -2.6 | -3.5 | -2.6 | -2.9 |
| Investing cash flow | -62.7 | -2.9 | -742 | 202 | 84.8 | -90.4 | 29.5 | -167 | -42.0 | -82.7 | -8.3 | -83.5 |
| Financing cash flow | -326 | -1.6 | 240 | -22.4 | -299 | -3.3 | -246 | 18.6 | 9.5 | -0.5 | -250 | 4.1 |
| Share repurchases | -331 | -1.6 | 0.0 | -38.9 | -300 | -3.3 | -250 | — | — | -0.5 | -252 | — |
| Debt issued | — | — | 1,470 | — | — | — | — | — | — | — | — | — |
| Debt repaid | — | — | -845 | — | — | — | — | — | — | — | — | — |
| Net change in cash | -148 | 176 | -283 | 358 | -114 | 60.5 | -38.5 | -33.5 | 23.2 | 46.3 | -156 | 53.1 |
| Free cash flow | 237 | 176 | 218 | 176 | 98.1 | 153 | 175 | 114 | 53.2 | 126 | 99.8 | 129 |
| Levered free cash flow | 189 | 147 | -104 | 105 | 80.2 | 104 | 139 | 106 | 53.0 | 104 | 76.0 | 102 |